Overview

STUDY TO COMPARE PHARMACOKINETICS (PK) OF SINGLE ORAL DOSES OF DIFFERENT PF-06882961 FORMULATIONS IN PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY

Status:
Completed

Trial end date:
2021-07-19

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the effect of formulation on relative bioavailability of PF-06882961.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer